Skip to main content
FDA approves 2nd CAR-T therapy candidate -- Yescarta by Gilead

Yescarta, or axicabtagene ciloleucel, the second drug in a new class of chimeric antigen receptor T-cell therapy products developed to treat cancer, was approved by the FDA for patients with diffuse large B cell lymphoma. The treatment, originally developed by Kite Pharma, was acquired by Gilead Sciences in August, and a single dose is expected to cost $373,000.

Full Story: